Inventor · Grayslake, IL, US

Lisa A. Hasvold

33Patents
9h-index
66Co-inventors
78Inventor score

Filing activity: Nov 21, 1996 → Oct 7, 2022

Most-cited inventions

PatentTitleAreaCited byStatus
US8563735B2 Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases Chemistry; Metallurgy 70 Active
US8546399B2 Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases Emerging Cross-Sectional Technologies 57 Active
US8586754B2 BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases Chemistry; Metallurgy 55 Active
US5703244A Process for preparation of chiral 3-amino-pyrrolidine and analogous bicyclic compounds Emerging Cross-Sectional Technologies 48 Expired
US8580794B2 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases Chemistry; Metallurgy 35 Active
US8232273B2 Heterocyclic compounds and methods of use Chemistry; Metallurgy 26 Active
US9034875B2 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases Chemistry; Metallurgy 16 Active
US9174982B2 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases Emerging Cross-Sectional Technologies 15 Active
US9315488B2 Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases Chemistry; Metallurgy 11 Active
US9073855B2 BCL-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseases Chemistry; Metallurgy 9 Active
US9045420B2 Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases Chemistry; Metallurgy 9 Active
US9303025B2 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases Emerging Cross-Sectional Technologies 9 Active
US9072748B2 BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases Chemistry; Metallurgy 9 Active
US8980879B2 Bromodomain inhibitors Emerging Cross-Sectional Technologies 9 Active
US9125913B2 Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases Chemistry; Metallurgy 8 Active
US8445679B2 7-substituted indole MCL-1 inhibitors Chemistry; Metallurgy 6 Active
US8148384B2 Substituted thieno[3,2-d]pyrimidine PIM kinase inhibitors as cancer chemotherapeutics Human Necessities 6 Active
US9050346B2 Bromodomain inhibitors Emerging Cross-Sectional Technologies 4 Active
US7211595B2 Farnesyltransferase inhibitors Chemistry; Metallurgy 4 Expired
US7456169B2 Heterocyclic kinase inhibitors Chemistry; Metallurgy 4 Active
US9296741B2 Bromodomain inhibitors Chemistry; Metallurgy 3 Active
US10035800B2 Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors Chemistry; Metallurgy 3 Active
US9957263B2 Bromodomain inhibitors Human Necessities 2 Active
US10633379B2 Bromodomain inhibitors Human Necessities 2 Active
US9321764B2 Dihydro-pyrrolopyridinone inhibitors Chemistry; Metallurgy 2 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.